Medical devices and pharmaceuticals: differences in public acceptance.

David Holmes, Douglas L. Wood

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

In the past 15 years, rapid technologic advances have introduced medical devices for clinical use that have transformed the care of patients with chronic diseases, especially heart disease. These devices have become truly lifesaving, and their effectiveness has been demonstrated in randomized clinical trials and cost-effectiveness studies. At the same time, a remarkable number of pharmaceutical agents with new actions and capabilities have also been introduced into clinical use. These new compounds have altered the practice of oncology and the care of patients with hematologic malignancies, sometimes with significant improvement in survival. There have been other drugs introduced to manage chronic diseases that alter quality of life but do not usually threaten survival. Recent problems related to the COX-2 anti-inflammatory drugs and ongoing controversies associated with them have raised public awareness; however, there is even more concern about device failures and recalls that have occurred during the same time frame. There is limited information as to why there is such an apparent difference in public opinion toward adverse drug events compared with device problems that lead to advisories or recalls. Among possible reasons are that an implantable device that requires a catheter-based surgical procedure, with its need for hospitalization and detailed explanation about all the potential risks, may be emotionally and intellectually processed differently by a patient/family compared with having a change in prescription from one drug to another.

Original languageEnglish (US)
Pages (from-to)269-272
Number of pages4
JournalThe American heart hospital journal
Volume4
Issue number4
StatePublished - Sep 2006

Fingerprint

Equipment and Supplies
Pharmaceutical Preparations
Patient Care
Chronic Disease
Equipment Failure
Public Opinion
Survival
Prescription Drugs
Hematologic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Cost-Benefit Analysis
Heart Diseases
Hospitalization
Anti-Inflammatory Agents
Catheters
Randomized Controlled Trials
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Medical devices and pharmaceuticals : differences in public acceptance. / Holmes, David; Wood, Douglas L.

In: The American heart hospital journal, Vol. 4, No. 4, 09.2006, p. 269-272.

Research output: Contribution to journalReview article

@article{258dcb833da34363af5e0ecf8d87cb2f,
title = "Medical devices and pharmaceuticals: differences in public acceptance.",
abstract = "In the past 15 years, rapid technologic advances have introduced medical devices for clinical use that have transformed the care of patients with chronic diseases, especially heart disease. These devices have become truly lifesaving, and their effectiveness has been demonstrated in randomized clinical trials and cost-effectiveness studies. At the same time, a remarkable number of pharmaceutical agents with new actions and capabilities have also been introduced into clinical use. These new compounds have altered the practice of oncology and the care of patients with hematologic malignancies, sometimes with significant improvement in survival. There have been other drugs introduced to manage chronic diseases that alter quality of life but do not usually threaten survival. Recent problems related to the COX-2 anti-inflammatory drugs and ongoing controversies associated with them have raised public awareness; however, there is even more concern about device failures and recalls that have occurred during the same time frame. There is limited information as to why there is such an apparent difference in public opinion toward adverse drug events compared with device problems that lead to advisories or recalls. Among possible reasons are that an implantable device that requires a catheter-based surgical procedure, with its need for hospitalization and detailed explanation about all the potential risks, may be emotionally and intellectually processed differently by a patient/family compared with having a change in prescription from one drug to another.",
author = "David Holmes and Wood, {Douglas L.}",
year = "2006",
month = "9",
language = "English (US)",
volume = "4",
pages = "269--272",
journal = "American Heart Hospital Journal",
issn = "1541-9215",
publisher = "Le Jacq Communications, Inc.",
number = "4",

}

TY - JOUR

T1 - Medical devices and pharmaceuticals

T2 - differences in public acceptance.

AU - Holmes, David

AU - Wood, Douglas L.

PY - 2006/9

Y1 - 2006/9

N2 - In the past 15 years, rapid technologic advances have introduced medical devices for clinical use that have transformed the care of patients with chronic diseases, especially heart disease. These devices have become truly lifesaving, and their effectiveness has been demonstrated in randomized clinical trials and cost-effectiveness studies. At the same time, a remarkable number of pharmaceutical agents with new actions and capabilities have also been introduced into clinical use. These new compounds have altered the practice of oncology and the care of patients with hematologic malignancies, sometimes with significant improvement in survival. There have been other drugs introduced to manage chronic diseases that alter quality of life but do not usually threaten survival. Recent problems related to the COX-2 anti-inflammatory drugs and ongoing controversies associated with them have raised public awareness; however, there is even more concern about device failures and recalls that have occurred during the same time frame. There is limited information as to why there is such an apparent difference in public opinion toward adverse drug events compared with device problems that lead to advisories or recalls. Among possible reasons are that an implantable device that requires a catheter-based surgical procedure, with its need for hospitalization and detailed explanation about all the potential risks, may be emotionally and intellectually processed differently by a patient/family compared with having a change in prescription from one drug to another.

AB - In the past 15 years, rapid technologic advances have introduced medical devices for clinical use that have transformed the care of patients with chronic diseases, especially heart disease. These devices have become truly lifesaving, and their effectiveness has been demonstrated in randomized clinical trials and cost-effectiveness studies. At the same time, a remarkable number of pharmaceutical agents with new actions and capabilities have also been introduced into clinical use. These new compounds have altered the practice of oncology and the care of patients with hematologic malignancies, sometimes with significant improvement in survival. There have been other drugs introduced to manage chronic diseases that alter quality of life but do not usually threaten survival. Recent problems related to the COX-2 anti-inflammatory drugs and ongoing controversies associated with them have raised public awareness; however, there is even more concern about device failures and recalls that have occurred during the same time frame. There is limited information as to why there is such an apparent difference in public opinion toward adverse drug events compared with device problems that lead to advisories or recalls. Among possible reasons are that an implantable device that requires a catheter-based surgical procedure, with its need for hospitalization and detailed explanation about all the potential risks, may be emotionally and intellectually processed differently by a patient/family compared with having a change in prescription from one drug to another.

UR - http://www.scopus.com/inward/record.url?scp=39049174315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049174315&partnerID=8YFLogxK

M3 - Review article

C2 - 17086007

AN - SCOPUS:39049174315

VL - 4

SP - 269

EP - 272

JO - American Heart Hospital Journal

JF - American Heart Hospital Journal

SN - 1541-9215

IS - 4

ER -